Therefore, we inquire whether these HCC-derived EGFR mutants can generate EGFR tyrosine phosphorylation in the absence of EGF, an indicator of constitutively active EGFR, and whether they are sensitive to erlotinib, an active 1st-generation EGFR-TKI. This evidence concerns the gene EGFR and hepatocellular carcinoma.